Allergan's anti-PTAB patent deal with the Mohawks looks to be a potential US game-changer 10 Sep 17
Allergan may just have driven a coach and horses through the inter partes review process at the Patent Trial and Appeal Board. The company’s agreement to transfer the six patents underpinning its dry-eye treatment Restasis to the Saint Regis Mohawks has been widely reported since it was announced on Friday. Under the deal, the Native American tribe will receive a one-off payment of $13.75 million from Allergan, then annual royalties of $15 million. Over the lifetime of the assets concerned that could represent a total of over $100 million – a sum which demonstrates just how valuable the pharma company believes those patents to be and how important it is they are kept away from the eyes of PTAB judges.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM magazine is, in my opinion, the premier magazine in the space of managing intellectual assets for value creation. It brings a fresh, business-driven perspective, rather than a purely legal perspective, on this issue. I would highly recommend it to anyone dealing with how to manage and drive value from intellectual assets.
David A VandenEinde
Assistant vice president and intellectual asset management leader
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email